Join to View Full Profile
825 Eastlake Ave EastLG-465Seattle, WA 98108
Phone+1 206-606-6324
Fax+1 206-606-1090
Dr. Chiorean is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1999 - 2002
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 1995 - 1998
Iuliu Hatieganu University of Medicine and PharmacyClass of 1993
Certifications & Licensure
WA State Medical License 2012 - 2027
IN State Medical License 2004 - 2013
MN State Medical License 1999 - 2004
MI State Medical License 1997 - 2001
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer Start of enrollment: 2005 May 01
- Metabolomics-Based Detection of Colorectal Cancer Start of enrollment: 2007 Jul 01
- Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas Start of enrollment: 2007 Sep 01
Publications & Presentations
PubMed
- Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT1...Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, Martin Whittle, Ben George
Cancers. 2026-02-03 - Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.Gentry G King, Kelsey K Baker, Andrew L Coveler, William P Harris, Stacey A Cohen
Cancers. 2025-05-30 - 7 citationsHMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.Naomi Yamamoto, Stephanie Dobersch, Ian Loveless, Annie N Samraj, Gun Ho Jang
Clinical Cancer Research. 2025-02-17
Press Mentions
New Study in JNCCN Supports Chemotherapy Option That Reduces Side Effects for People with Gastrointestinal CancersSeptember 5th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
